CASI:NSD-CASI Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.43

Change

+0.05 (+2.10)%

Market Cap

USD 0.29B

Volume

0.18M

Average Target Price

USD 5.00 (+105.76%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited, Juventas Cell Therapy Ltd., and Pharmathen Global BV. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-4.74 (-3.01%)

USD62.38B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.45 (+0.64%)

USD58.99B 22.23 17.39
REGN Regeneron Pharmaceuticals, Inc

-6.39 (-1.28%)

USD53.23B 18.28 14.53
SGEN Seagen Inc

-0.93 (-0.52%)

USD32.25B 68.04 62.62
BNTX BioNTech SE

+1.32 (+1.11%)

USD29.16B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

-0.55 (-0.45%)

USD26.49B 28.09 26.92
RPRX Royalty Pharma plc

+0.68 (+1.61%)

USD26.44B 22.60 9.98
GMAB Genmab A/S

+0.10 (+0.26%)

USD24.77B 26.59 2.61
BGNE BeiGene, Ltd

+1.57 (+0.71%)

USD20.63B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CASI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.36% 31% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.36% 31% F 20% F
Trailing 12 Months  
Capital Gain -24.30% 27% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.30% 27% F 16% F
Trailing 5 Years  
Capital Gain 140.59% 84% B 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 140.59% 84% B 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 77.40% N/A N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 77.40% N/A N/A 95% A
Risk Return Profile  
Volatility (Standard Deviation) 191.09% N/A N/A 4% F
Risk Adjusted Return 40.50% N/A N/A 62% D-
Market Capitalization 0.29B 49% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.28 60% D- 41% F
Price / Cash Flow Ratio -12.69 69% D+ 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -42.85% 68% D+ 25% F
Return on Invested Capital -51.48% 59% F 19% F
Return on Assets -17.67% 72% C- 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.64 58% F 44% F
Short Percent 2.13% 80% B- 60% D-
Beta 0.42 90% A- 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.